Legionella News and Research

RSS

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010

Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

8 Apr 2010

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

10 Mar 2010

Microbial Pathogenomics: A collection of reviews and future trends in bacterial pathogenomics

'Microbial Pathogenomics' contains a unique collection of reviews demonstrating how genomics has revolutionized our understanding of virulence, host-adaptation strategies and the evolution of bacterial pathogens. Current technologies - computational tools and functional approaches to genome analysis - are carefully documented and clearly illustrated.

23 Dec 2009

Eastern Technology Council names Puricore as winner of the Emerging Life Sciences Company of the Year

PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, was named as winner of the Emerging Life Sciences Company of the Year award, at the Eastern Technology Council’s 17th annual Enterprise Awards gala.

4 Dec 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

Puricore reports increase in sales of 25% in Q3

PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today issues an Interim Management Statement covering the three-month and nine-month periods ending September 30, 2009.

3 Nov 2009

Researchers find SNARE-like protein system to help bacteria avoid cell destruction

Infectious diseases currently cause about one-third of all human deaths worldwide, more than all forms of cancer combined. Advances in cell biology and microbial genetics have greatly enhanced understanding of the cause and mechanisms of infectious diseases.

12 Oct 2009

Clinical data emphasizing on efficacy and potency of torezolid to be presented

Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA.

14 Sep 2009

Puricore announces closure of its new USD 2.1 million debt facility

PuriCore plc (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces that it has closed on a new USD2.1 million debt facility with Republic First Bank.

26 Aug 2009

PuriCore reduces operating expenses by 14% in H1 2009 when compared with H1 2008

PuriCore (LSE: PURI), the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces its interim results for the six months ending June 30, 2009. An H1 2009 Operating and Financial Report and detailed financial results are available here at PuriCore’s website.

25 Aug 2009

Repeated stress signals made in cells with metabolism-associated disease encourage the growth of invading bacteria

Mitochondrial diseases disrupt the power generating machinery within cells and increase a person's susceptibility to bacterial infection, particularly in the lungs or respiratory tract.

28 Jul 2009

Sagent Pharmaceuticals receives FDA approval of Azithromycin for injection

Sagent Pharmaceuticals, Inc. has announced U.S. Food and Drug Administration (FDA) approval of azithromycin for injection, a semi-synthetic, macrolide antibiotic that is used to treat a wide variety of bacterial infections. Sagent will offer azithromycin in a 500 mg vial for intravenous use.

26 Mar 2009

FDA approves new indication for Wyeth's Tygacil (tigecycline)

Wyeth Pharmaceuticals, a division of Wyeth has announced that the U.S. Food and Drug Administration (FDA) approved Tygacil (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.

24 Mar 2009

Bioinformatics sheds light on evolutionary origin of Rickettsia virulence genes

Scientists from the Virginia Bioinformatics Institute (VBI) at Virginia Tech, the University of Maryland School of Medicine, and the University of Louisville have revealed that genes for a specific type of molecular secretion system in Rickettsia, a structure that is linked in many cases to virulence, have been conserved over many years of evolution.

11 Mar 2009

Discovery of novel ways to halt the spread of antibiotic resistance

Scientists have identified the structure of a key component of the bacteria behind such diseases as whooping cough, peptic stomach ulcers and Legionnaires' disease.

9 Jan 2009

Scientists uncover molecule that keeps pathogens like salmonella in check

Scientists at UT Southwestern Medical Center have found a potential new way to stop the bacteria that cause gastroenteritis, tularemia and severe diarrhea from making people sick.

21 Aug 2008

Is mankind contaminating space?

Life in outer space is an absolute certainty, and it is likely to be more familiar than we might think, according to an article in the May issue of Microbiology Today. Ever since the start of the space race we have sent more than just satellites and astronauts into space: spacecraft are not routinely decontaminated and are teeming with microbial life.

28 May 2008

New insights into Legionella pneumophila

A study published online in Genome Research (www.genome.org) describes new insights into Legionella pneumophila, the bacteria responsible for most cases of Legionnaires' disease.

7 Feb 2008

Legionnaire's bacterial proteins work together to survive

Proteins within the bacteria that cause Legionnaire's disease can kidnap their own molecular "coffin" and carry it to a safe place within the cell, ensuring their survival, Yale School of Medicine researchers report in Nature Wednesday.

24 Oct 2007